Trial site
Macquarie University Hospital
Macquarie Park, New South Wales 2109, AustraliaNot linked to an institution yet
- 10running trials
- 3closed trials
The trials here
What the 13 trials at this site are about, from their registry records.
- Phase
- Phase 25 trials
- Phase 35 trials
- Phase 2/32 trials
- Phase 11 trial
- Status
- Active, not recruiting6 trials
- Recruiting4 trials
- Completed2 trials
- Terminated1 trial
- Lead sponsor
- Hoffmann-La Roche5 trials
- Australian and New Zealand Urogenital and Prostate Cancer Trials Group2 trials
- Adcendo ApS1 trial
- Biogen1 trial
- Eisai Inc.1 trial
- and 3 more
Running trials
Recruiting
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer
NCT07659795· Phase 2· Verastem, Inc.· Source
Contact: Sam Ly
Recruiting
RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive
NCT07413939· Phase 2/3· Hoffmann-La Roche· Source
Recruiting
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
NCT06819891· Phase 3· Hoffmann-La Roche· Source
Active, not recruiting
FPI-2265 (225Ac-PSMA-I&T) and Olaparib for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
NCT06909825· Phase 2· Fusion Pharmaceuticals Inc.· Source
Active, not recruiting
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis
NCT06588855· Phase 3· Hoffmann-La Roche· Source
Recruiting
ADCE-T02, a Tissue Factor Targeted Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours
NCT06597721· Phase 1· Adcendo ApS· Source
Contact: Sherri Paxton
Active, not recruiting
Study to Learn If Tofersen (BIIB067) Can Delay ALS Symptoms and About Its Safety in Adults With a SOD1 Gene Mutation Who Have Not Yet Developed ALS Symptoms
NCT04856982· Phase 3· Biogen· Source
Active, not recruiting
Enzalutamide With Lu PSMA-617 Versus Enzalutamide Alone in Men With Metastatic Castration-resistant Prostate Cancer
NCT04419402· Phase 2· Australian and New Zealand Urogenital and Prostate Cancer Trials Group· Source
Active, not recruiting
A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Participants With PIK3CA-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer
NCT04191499· Phase 2/3· Hoffmann-La Roche· Source
Active, not recruiting
Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma
NCT02811861· Phase 3· Eisai Inc.· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error